Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage

I-Chin Wu, Ching-Lung Lai, Steven-Huy Han, Kwang-Hyup Han, Stuart Gordon, You-Chen Chao, Chee-Kiat Tan, William Sievert, Tawesak Tanwandee, Dong Xu, Boon-Leong Neo, Ting-Tsung Chang

Research output: Contribution to journalArticleResearchpeer-review

43 Citations (Scopus)


Current guidelines for management of chronic hepatitis B recommend treatment for patients presenting with elevated hepatitis B virus (HBV) DNA and alanine aminotransferase (ALT) >2 x upper limit of normal (ULN) or histological evidence of liver disease. Retrospective analyses have demonstrated that significant hepatic necroinflammation and fibrosis were present in a substantial proportion of patients with ALT 1 to 2 x ULN. To assess therapeutic efficacy in this clinical setting, we retrospectively examined treatment endpoints among the subset of nucleoside-na??ve chronic hepatitis B (CHB) patients treated in phase 3 clinical trials of entecavir who had both screening and baseline serum ALT 1.3 to 2 x ULN. A total of 1347 patients were randomized to treatment with entecavir or lamivudine.
Original languageEnglish
Pages (from-to)1185 - 1189
Number of pages5
Issue number4
Publication statusPublished - 2010

Cite this